GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » EV-to-FCF

Galapagos NV (FRA:GXE) EV-to-FCF : 3.63 (As of Mar. 03, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Galapagos NV's Enterprise Value is €-1,459.7 Mil. Galapagos NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-402.1 Mil. Therefore, Galapagos NV's EV-to-FCF for today is 3.63.

The historical rank and industry rank for Galapagos NV's EV-to-FCF or its related term are showing as below:

FRA:GXE' s EV-to-FCF Range Over the Past 10 Years
Min: -78.73   Med: 1.74   Max: 12.32
Current: 3.63

During the past 13 years, the highest EV-to-FCF of Galapagos NV was 12.32. The lowest was -78.73. And the median was 1.74.

FRA:GXE's EV-to-FCF is ranked better than
50.36% of 417 companies
in the Biotechnology industry
Industry Median: 4.41 vs FRA:GXE: 3.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-03), Galapagos NV's stock price is €25.02. Galapagos NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €1.120. Therefore, Galapagos NV's PE Ratio (TTM) for today is 22.34.


Galapagos NV EV-to-FCF Historical Data

The historical data trend for Galapagos NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV EV-to-FCF Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 2.58 2.51 2.91 3.38

Galapagos NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 3.52 4.11 3.94 3.38

Competitive Comparison of Galapagos NV's EV-to-FCF

For the Biotechnology subindustry, Galapagos NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Galapagos NV's EV-to-FCF falls into.



Galapagos NV EV-to-FCF Calculation

Galapagos NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-1459.742/-402.136
=3.63

Galapagos NV's current Enterprise Value is €-1,459.7 Mil.
Galapagos NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-402.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (FRA:GXE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Galapagos NV's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.02/1.120
=22.34

Galapagos NV's share price for today is €25.02.
Galapagos NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Galapagos NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV Headlines

No Headlines